About Glostem
Glostem offers products and services including Conference Management and Lead Generation.
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Social LinkedIn X Facebook Instagram
- Legal Name Glostem Private Limited
- Date of Incorporation 23 Jul, 2012
- Jurisdiction Chandigarh, India
- Annual Revenue₹1.40 Cr
FY 2025 · +6% YoY
- Net Profit₹36.2 Lakh
FY 2025 · 26% margin
- EBITDA₹50.7 Lakh
FY 2025 · 36% margin
Associated legal entities of Glostem
Glostem operates through Glostem Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Glostem Private Limited CIN U91990CH2012PTC033929 | Active | 23 Jul 2012 | Chandigarh, Chandigarh | ₹1.4 Cr | – | 2 | View details |
Products & Services of Glostem
Glostem offers a comprehensive portfolio of products and services, including Conference Management and Lead Generation.
Conference management services are offered, including registration, exhibition, and abstract handling for scientific events.
Lead generation services are provided for research, instruments, and products targeted at scientific communities.
Board of directors of Glostem Private Limited (Glostem)
Glostem Private Limited is the primary company behind Glostem. The board of Glostem Private Limited currently have 2 directors; the longest-serving is Sanjay Bajaj, appointed in 2012. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sanjay Bajaj DIN 05326282 | Director | 23 Jul 2012 | 14 yrs 2 mo | Glostem Private Limited |
| Usha Bhatia DIN 08990070 | Additional Director | 10 Dec 2020 | 5 yrs 10 mo | Glostem Private Limited |
Financials of Glostem
Figures of Glostem Private Limited, the primary company behind Glostem, for FY 2025. Revenue was ₹1.40 Cr (+6% year on year). Net profit was ₹36.2 Lakh (26% margin). EBITDA was ₹50.7 Lakh (36% margin). Revenue has grown at a compounded annual rate of +49% over three years and +5% over five years.
- ₹1.40 CrRevenue · FY 2025 · +6% YoY
- ₹36.2 LakhNet profit · 26% margin
- ₹50.7 LakhEBITDA · 36% margin
- ₹1 LakhPaid-up capital
- +49%Revenue CAGR, 3 years
- +5%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Glostem Private Limited are on its company page.
Detailed financial statements for Glostem
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to Glostem
10 companies that operate in the same segment as Glostem (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Glostem
The primary company behind Glostem, Glostem Private Limited, reported revenue of ₹1.40 Cr for FY 2025, up 6% year on year.
Glostem is identified as a provider of technical, business, event, and virtual assistant services in the pharmaceutical, bioscience, and technology industries. Services such as lead generation, regulatory affairs, and conference management have been offered since 2013, supporting scientific communities through research solutions, commercialization assistance, and laboratory setup. Partnerships with entities like Agilent Technologies and Merck are maintained, while operations are based in Chandigarh, India, focusing on areas like drug discovery and genomics without promotional emphasis.
Glostem offers Conference Management and Lead Generation.
Glostem operates through Glostem Private Limited.
The legal entities of Glostem currently have 2 directors, including Usha Bhatia, Sanjay Bajaj.